These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24390275)

  • 21. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer.
    Kishan AU; Tendulkar RD; Tran PT; Parker CC; Nguyen PL; Stephenson AJ; Carrie C
    Eur Urol Oncol; 2018 May; 1(1):3-18. PubMed ID: 31100226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study.
    Miyake M; Tanaka N; Asakawa I; Morizawa Y; Anai S; Torimoto K; Aoki K; Yoneda T; Hasegawa M; Konishi N; Fujimoto K
    Radiat Oncol; 2014 Oct; 9():208. PubMed ID: 25331298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram.
    Meijer HJ; Debats OA; Roach M; Span PN; Witjes JA; Kaanders JH; van Lin EN; Barentsz JO
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1186-91. PubMed ID: 22520482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
    Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
    Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
    Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial.
    Katayama S; Habl G; Kessel K; Edler L; Debus J; Herfarth K; Sterzing F
    BMC Cancer; 2014 Jan; 14():20. PubMed ID: 24422782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
    Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
    Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
    Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
    Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram.
    Hugen CM; Polcari AJ; Quek ML; Garza RP; Fitzgerald MP; Flanigan RC
    World J Urol; 2010 Dec; 28(6):741-4. PubMed ID: 20449749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy.
    Holliday EB; Kuban DA; Levy LB; Bolukbasi Y; Master P; Choi S; Nguyen Q; McGuire SE; Mahmood U; Frank SJ; Hoffman KE
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):389-394. PubMed ID: 28462945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.
    Kruser TJ; Jarrard DF; Graf AK; Hedican SP; Paolone DR; Wegenke JD; Liu G; Geye HM; Ritter MA
    Cancer; 2011 Jun; 117(12):2629-36. PubMed ID: 21656740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial.
    Müller AC; Zips D; Heinrich V; Lamprecht U; Voigt O; Burock S; Budach V; Wust P; Ghadjar P
    Radiat Oncol; 2015 Jul; 10():138. PubMed ID: 26152590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.
    Kabarriti R; Ohri N; Hannan R; Tishbi N; Baliga S; McGovern KP; Mourad WF; Ghavamian R; Kalnicki S; Guha C; Garg MK
    Pract Radiat Oncol; 2014; 4(6):409-14. PubMed ID: 25407863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse.
    Weidner AM; van Lin EN; Dinter DJ; Rozema T; Schoenberg SO; Wenz F; Barentsz JO; Lohr F
    Strahlenther Onkol; 2011 Mar; 187(3):206-12. PubMed ID: 21347637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation therapy post radical prostatectomy: who, when and why?
    Latorzeff I; Le Guevelou J; Sargos P
    Curr Opin Support Palliat Care; 2023 Mar; 17(1):47-54. PubMed ID: 36367534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.